Neutral
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
Nurix Therapeutics announced updated Phase 1a/b clinical trial data for bexobrutideg, an oral BTK degrader, in patients with chronic lymphocytic leuke...